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ABSTRACT 
Purpose 
Smoking cessation after diagnosis of lung, bladder, and upper aerodigestive tract cancer 
appears to improve survival and support to quit would improve cessation. The aims of this 
study were to assess how often general practitioners (GPs) provide active cessation support in 
these patients and whether this is influenced by incentive payments.  
 
Methods 
Using electronic primary care records from the UK Clinical Practice Research Datalink 
(CPRD), 12,393 incident cancer cases diagnosed between 1999-2013 were matched 1:1 with 
incident coronary heart disease (CHD) patients.  We assessed differences in the proportion 
whose GPs updated smoking status, advised quitting, prescribed cessation medications, or 
stopped smoking within a year of diagnosis and whether any differences arose because GPs 
were incentivised to address smoking in patients with CHD and not cancer.  
 
Results 
At diagnosis, 32·0% of patients with cancer and 18·2% of patients with CHD smoked.  
Patients with cancer were less likely than patients with CHD to have GPs update smoking 
status (OR 0·18 (95%CI 0·17-0·19)), advise quitting (OR 0·38 (95%CI 0·36-0·40)), 
prescribe medication (OR 0·67 (95%CI 0·63-0·73)), or stop smoking (OR 0·76 (95%CI 0·69-
0·84)).  61.7% of people with cancer and 55·4% with CHD who smoked at diagnosis were 
smoking one year later.  Introducing incentives was associated with more frequent 
intervention but not for CHD patients specifically.   
 
Conclusions 
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General practitioners are less likely to support smoking cessation in patients with cancer than 
CHD and patients with cancer are less likely to stop smoking, and this is not due to the 
difference in incentive payments. 
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INTRODUCTION 
A fifth of cancers in the UK are attributable to tobacco smoke,(1) of which lung, bladder and 
upper aerodigestive tract cancers are most common.(1, 2)  Continued smoking after diagnosis 
of cancer is associated with worse prognosis.(3-5) Estimates suggest that between 35% and 
62% of cancer patients continue smoking in the year after diagnosis.(6-11)  
 
A cancer diagnosis motivates people to attempt to quit smoking. (12) Physicians can improve 
motivation and the likelihood of achieving abstinence by offering assistance, including giving 
advice and prescribing medication.(13, 14) However, many physicians do not view 
supporting smoking cessation as a priority.(15) In 2004, the UK introduced a pay for 
performance scheme, the Quality and Outcomes Framework (QOF), which includes 
incentivisation to support smoking cessation.  Payments are made for recording smoking 
status and offering ‘support and treatment’ annually to patients with one of several smoking-
related conditions, but this does not include smoking-related cancers.(16)  It is not known to 
what extent GPs are supporting cancer patients to quit, or if introduction of incentives for 
other conditions has influenced this. 
 
The first aim of this study was to examine how often GPs intervene to support smoking 
cessation in patients with cancer, meaning how often they updated smoking status and 
provided support, and to examine the proportion of patients that manage to stop in the first 
year after diagnosis.  Hospital physicians infrequently offer active support for smoking 
cessation so primary care support is crucial.(17-20)  For context, we compared cancer with 
patients with coronary heart disease (CHD), a similarly serious smoking-related condition 
which also motivates people to try to stop smoking and for which there is evidence that 
smoking cessation improves disease outcomes.(21) A second aim was to examine the effect 
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of incentive payments on management of smoking in patients with CHD.  CHD is a condition 
in which doctors are incentivized to provide smoking cessation support.  If the management 
of smoking improved in patients with CHD but not cancer after the payments were 
introduced, this would support extending these incentive payments to cover patients with 
smoking-related cancers too.  
 
METHODS 
We conducted a retrospective cohort study using routinely collected UK primary care records 
from the Clinical Practice Research Datalink (CPRD) (www.cprd.com).  In 2013, this 
contained records from 4.4 million live patients, 6.9% of the UK population.(22)  The 
protocol was peer-reviewed then approved by the Independent Scientific Advisory 
Committee (ISAC) for MHRA database research (ref no: 14_105) and was available during 
peer review.   
 
Incident cases of lung, bladder and upper aerodigestive tract cancers diagnosed between 1999 
and 2013 that had a recording of smoking at diagnosis or within three years of diagnosis, 
were matched 1:1 to incident CHD controls based on year of diagnosis, general practice and 
smoking status.  We included patients who smoked at diagnosis or who had stopped within 
three years of diagnosis as people who have recently stopped are vulnerable to relapse during 
this time,(23) and doctors are incentivized by QOF to ask patients about smoking for up to 
three years after quitting.  We defined smoking at diagnosis as smoking on the last occasion 
smoking status was recorded in the three years prior to diagnosis.  A recent ex-smoker was 
defined someone recorded as smoking within three years of diagnosis and subsequently 
recorded as not smoking on the last occasion prior to diagnosis.    Patients were followed until 
the end of 2013.  We adapted the protocol to exclude thyroid cancers, because they are not 
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smoking-related, and to exclude people who had been stopped for over three years or never 
smokers because they are not relevant to the study questions.   
 
For the first aim, we compared the proportion of patients in whom GPs updated smoking 
status, advised patients to stop or provided advice on how to do so, prescribed cessation 
medication, and quit smoking during the year after diagnosis.  This is presented as a 
proportion of current smokers and recent ex-smokers.  With logistic regression we examined 
differences in outcomes between cancer cases and CHD controls.  All models were adjusted 
for age, gender, and the presence of  co-morbidity for which intervention on smoking is 
incentivized by the QOF- asthma, chronic kidney disease, chronic obstructive pulmonary 
disease, peripheral artery disease, diabetes, hypertension, stroke and serious mental illness.  
In sensitivity analyses we excluded patients who were not smoking at diagnosis.  Because 
GPs may not intervene on smoking in patients who are known to be terminally ill, we also 
conducted sensitivity analyses restricted to patients who survived at least one year after 
diagnosis.   We calculated the adjusted incidence rate ratio (RR) for cancer patients relative to 
CHD patients for number of smoking cessation prescriptions given using negative binomial 
regression (to account for over-dispersion).  We assessed whether incentives increased the 
frequency of GP intervention by adding a binary term reflecting whether or not the year of 
diagnosis was prior to or after 2004, the year incentives were introduced.  We added a 
multiplicative interaction term to examine whether the apparent effect of incentives differed 
between cases with cancer and controls with CHD; the latter attracted incentive payments. 
 
RESULTS 
There were 42,112 people who were diagnosed with lung, bladder or upper aerodigestive 
tract cancer between the start of 1999 and end of 2013.  Of these, 13,449 (32·0%) were 
8 
 
smoking at diagnosis and 3,092 (7·3%) had stopped smoking within three years of diagnosis 
There were 159,182 people diagnosed with CHD during this period, of whom 28,987 
(18·2%) smoked at diagnosis and 6,301 (4·0%) had stopped smoking within three years of 
diagnosis.  Of these groups, 12,393 cancer cases were successfully matched to the same 
number of CHD controls and were included in the main analyses.  There were 9,347 people 
with lung cancer (86% current smokers), 2,050 with bladder cancer (90% current smokers), 
with upper aerodigestive tract cancers (91% current smokers).  Sensitivity analyses of people 
who had survived for at least one year, included 5,094 incident cancer cases (2,781 lung, 
1,512 bladder, 801 upper aerodigestive) and 5,094 matched CHD controls.   
Cancer patients were older at diagnosis (67·5yrs. (SD 10·5) v 61·3yrs. (SD 11·9)), less likely 
to be male (57·9% v 65·6%) and had higher prevalence of asthma, chronic obstructive 
pulmonary disease (COPD), chronic kidney disease, stroke, and peripheral artery disease and 
a lower prevalence of hypertension and diabetes (Table 1).  
 
Updating of smoking status 
Cancer patients were significantly less likely to have their smoking status updated during the 
first year after diagnosis than controls (37% v 78%, OR 0·18 (95%CI 0·17-0·19)).  After 
removing patients who died within a year of diagnosis, this difference was smaller but still 
apparent (62% v 86%, OR 0·26 (95%CI 0·23-0·29)) (Table 2, Figure 1a). 
 
There was an almost three-fold increase in the odds of updating of smoking status after 
incentives were introduced (OR 2·71 (95%CI 2·44-2·99)).  There was no evidence that the 
increase was larger in CHD compared with cancer (p interaction=0·86) (Appendix Table 1). 
 
Advice to quit 
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Cancer patients were significantly less likely to have a recording of advice to quit (all patients 
23% v 45%, OR 0·38 (95%CI 0·36-0·40).  When including patients who were smoking at 
diagnosis only, the proportions were similar (24% v 48%, OR 0·36 (95%CI 0·34-0·38).  In 
the cohort that survived at least a year the proportions were 39% v 51%, OR 0·60 (95%CI 
0·55-0·66) (Table 2, Figure 1b).   
 
There was a threefold increase in the odds of recording advice to quit after the introduction of 
incentives (OR 3·04 (95%CI 2·73-3·38). There was evidence that the increase in odds was 
greater for cancer patients than for CHD controls (p interaction=0·02), and subgroup analyses 
showed that this was confined to lung cancer patients (Appendix Table 2).  
 
Prescription of smoking cessation medications 
Cancer patients were significantly less likely to be prescribed smoking cessation medications 
(all patients 12% v 21%, OR 0·67 (95%CI 0·63-0·73); current smokers at diagnosis only 
13% v 22%, OR 0·67 (95%CI 0.62-0.72)).  However, this difference was smaller and not 
significant confined to people who survived at least a year (21% v 23%, OR 1·05 (95%CI 
0·94-1·17)) (Table 2, Figure 1c).  The number of prescriptions given to cancer patients was 
similar to the number given to CHD controls, RR 0·95 (95%CI 0·87-1·04).  Restricted to 
those surviving a year it was 1·15 (95%CI 1·01-1·32) indicating that cancer patients were 
given more prescriptions than CHD controls.  
   
There was a significant increase in proportion of patients receiving smoking cessation 
medications after introduction of the QOF (OR 1·79 (95%CI 1·56-2·05).  There was no 
evidence that this change in the odds of prescribing at least one medication differed for 
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cancer or CHD patients (p interaction=0·89). Findings were similar in cancer subgroups 
matched to CHD controls (Appendix Table 3). 
 
Smoking cessation 
Of the 3,706 cancer/CHD patients who smoked at diagnosis and had at least one smoking 
status update in the year following diagnosis, 1,359 (36·7%) of patients with cancer and 
1,645 (44·4%) of patients with CHD stopped smoking, OR 0·76 (95%CI 0·69-0·84).  Among 
2253 pairs both of whom had smoking status updated and survived at least a year, 863 
(38·3%) of people with cancer and 1004 (44·6%) of people with CHD stopped smoking, OR 
0·82 (95%CI 0·72-0·93) (Table 3).   
 
There was no significant increase in quitting after introduction of incentives (OR 1·18 
(95%CI 0·94-1·49) (Appendix Table 4).  
 
DISCUSSION 
A third of people with lung, bladder, and upper aerodigestive tract cancer smoked at 
diagnosis.  People with cancer were less likely to have smoking status recorded by their GP, 
be given advice, be prescribed cessation pharmacotherapy, or quit smoking in the year 
following diagnosis. Confining the analysis to patients who smoked at the time of diagnosis 
and to those with a better prognosis did not change these findings except that the difference in 
prescription of pharmacotherapy was no longer apparent.  The frequency of recording of 
smoking status, advice and pharmacotherapy increased after introduction of incentive 
payments for GPs to manage smoking but there were no differences in the rates of quitting.  
As these payments were confined to the management of smoking in patients with CHD and 
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not cancer, we expected to see the improvement to be larger in the CHD group.  However, 
there was no evidence of this and some evidence of the reverse. 
 
Strengths and weaknesses  
This is the first study to investigate how GPs manage smoking in patients with smoking-
related cancer.  An important strength is that the population of patients and GPs who provide 
data to CPRD is broadly representative of the general UK population. (22)  The sample was 
large enough to give precise estimates of association.  Like all observational studies, we are 
unable to conclude that the lower rates of GP intervention on smoking in cancer patients were 
due to the GP not prioritising smoking in this group specifically.  One plausible explanation 
could be that patients with cancer were less likely to consult GPs than were patients with 
CHD.  However, there was no evidence of this.  Ninety-one percent of all patients with a new 
diagnosis of cancer were seen by their GP in the year after diagnosis and 95% of all cancer 
patients who survived at least a year, compared with 75% and 79% of patients with CHD.  
Another explanation could lie in differences in expected survival between patients with lung 
cancer in particular and patients with CHD.  Arguably, it is inappropriate for GPs to intervene 
on smoking in patients with only months to live and many patients diagnosed with lung 
cancer survive for less than a year.(24)  To see if difference in management was driven by 
expectations of poor prognosis, we did sensitivity analyses using only patients that survived a 
year. We had originally planned to assess the effect of expected prognosis by adjusting for 
treatment intent and cancer staging at diagnosis but the data were not available in the level of 
Hospital Episode Statistics (HES) we had.  Limiting analysis to patients who survived at least 
a year narrowed but generally did not abolish the difference between cancer and CHD.  An 
additional reason for lower GPs intervention may be that cancer patients are more likely to 
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report receiving help from secondary care.  However, support for smoking cessation in 
secondary care is low and this is unlikely to be the main source of cessation support.(17-20)   
As with all studies based on healthcare records, it is possible that GPs provided advice to quit 
or on how to quit and did not record this.  While this would underestimate the true rate of 
intervention, it is likely to underestimate the frequency of intervention in patients with cancer 
and CHD equally and is thus an implausible explanation for the findings.  Given the way 
records work, all prescriptions given by GPs would have been recorded and thus these data 
can be regarded as true estimates of the frequency of intervention.  It is also likely that some 
people stopped smoking and, because GPs did not ask, this was not recorded or patients may 
claim to have stopped smoking when this is not the case.  While our estimate of cessation 
may therefore be inaccurate to some degree, any error should affect patients with cancer and 
CHD to a similar extent.  Thus it appears that GPs are less assiduously supporting patients 
with cancer to stop smoking than they do for people with CHD to the detriment of people 
with cancer.   
 
Interpretation of findings and comparison with existing studies 
Many GPs express negative attitudes towards supporting smoking cessation in general.(15) 
This includes concerns about lack of time, ineffectiveness of interventions and lack of 
training.  However, these concerns would deter intervening in patients with lung cancer and 
CHD equally. Two recent international surveys of cancer specialists found that less than half 
routinely offered patients smoking cessation treatment; common concerns were that 
intervention would be ineffective and cancer patients would resist treatment.(18, 19)  
However, we have previously reported that patients treated surgically for lung cancer express 
a wish for much greater involvement of clinicians in helping them manage smoking, and so 
this concern may be unfounded.(25)  Whether or not GPs view smoking cessation support as 
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an equal priority is perhaps a secondary concern, however, because data indicate considerable 
scope for increasing active management both in cancer and CHD.  Only a minority of patients 
receive advice to quit and just over a fifth are prescribed pharmacotherapy, while about six in 
10 report smoking one year after the diagnosis of cancer or CHD.   
 
The second aim was to examine the impact of payment to GPs on management of smoking.   
We found that recording of status and advice was higher on average in the post-QOF period 
than before incentives were introduced in 2004.  Given the size of effect and the sharp rise 
that occurred around the time of introducing the incentive payments, it is likely that this was 
a change brought about by the new payment system, as has been noted in previous 
studies.(26, 27)  However, counterintuitively, we found that the increase applied equally to 
both patients with cancer, who did not attract payments, as to patients with CHD who did.  
Furthermore, the absolute rates of prescription of smoking cessation medications were small, 
and again although this increased after introduction of the QOF, the size of the increase for 
cancer and CHD patients was similar.  Although GP intervention for smoking has been 
shown to be effective at increasing smoking cessation rates,(14) and clearly incentive 
payments will have the desired benefit to health if activity leads patients to quit smoking(28) 
this finding casts doubt on the specific benefits of extending the coverage of incentives for 
patients with smoking-related cancers. 
 
CONCLUSIONS 
Our data show that cancer patients receive less support to quit smoking in primary care than 
patients with CHD.  Although absolute rates have improved over time they remain lower than 
they could be.  The higher rate of intervention seen in patients with CHD than with cancer is 
not due to the effect of incentive payments.  Cancer patients would benefit if GPs became 
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more actively involved in supporting smoking cessation and it is important to find ways to 
improve the management of smoking cessation by GPs for patients with cancer.   
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Table 1. Distribution of baseline characteristics in all cancer cases and matched CHD 
controls diagnosed between 1999 and 2013.  
Characteristics  Category All Cancer 
patients 
 
CHD patients  
 
n= 12,393 n= 12,393 
Gender, n (%) Male  7185 (57.9) 8126 (65.6) 
Female 5208 (42.1) 4267 (34.4) 
Age yrs., mean (SD) Years 67.5 (10.5) 61.3 (11.9) 
Smoking status at 
diagnosis 
Current 10794 (87.1) 10794 (87.1) 
< 3yr Ex-smoker 1599 (12.9) 1599 (12.9) 
Index of multiple 
deprivation, n (%) 
1 (least deprived) 925 (7.5) 934 (7.5) 
 2 1315 (10.6) 1372 (11.1) 
 3 1423 (11.5) 1414 (11.4) 
 4 1758 (14.2) 1690 (13.6) 
 5 (most deprived) 1764 (14.2) 1773(14.3) 
 Missing 5208 (42) 5210 (42) 
Frequency of smoking, n 
(%)  
Light 1496 (13.9) 1367 (12.7) 
 Moderate 2093 (19.4) 1981 (18.4) 
 Heavy 1788 (16.6) 1794 (16.6) 
 Frequency 
unknown 
5417 (50.2) 5652 (52.4) 
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Asthma, n (%) No 11271 (91) 11456 (92.4) 
Yes 1122 (9) 937 (7.6) 
Chronic kidney disease, 
n (%) 
No 11481 (92.6) 11767 (94.9) 
Yes 912 (7.4) 626 (5.1) 
Chronic obstructive 
pulmonary disease, n 
(%) 
No 9642 (77.8)  11091 (89.5) 
Yes 2751 (22.2) 1302 (10.5) 
Diabetes, n (%) No 11339 (91.5) 11182 (90.2) 
Yes 1054 (8.5) 1211 (9.8) 
Hypertension, n (%) No 9887 (79.8) 9658 (77.9) 
Yes 2506 (20.2) 2735 (22.1) 
Peripheral arterial 
disease, n (%) 
No 11517 (92.9) 11649 (94) 
Yes 876 (7.1) 744 (6) 
Stroke, n (%) No 11582 (93.5) 11790 (95.1) 
 Yes 811 (6.5) 603 (4.9) 
Psychosis, n (%) No 12289 (99.2) 12306 (99.3) 
 Yes 104 (0.8) 87 (0.7) 
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Table 2: Number (%) of cancer and CHD patients diagnosed between 1999 and 2013  whose smoking status is updated, were advised to 
quit and were prescribed smoking cessation medication within the first year after diagnosis, and odds ratio (OR) for these outcomes in 
cancer patients relative to matched CHD patients 
 Smokers and <3 yrs . ex-smokers  
 (Al l  cancer n= 12, 393, CHD n= 12, 393)* 
 
Current smokers only 
(Al l  cancer n= 10, 794, CHD n= 10, 794)** 
 
1 year+ survivors only 
(Al l  cancer n = 4, 228, CHD n=4, 228)*** 
Outcome Cancer case  
n (%) 
CHD control   
n (%) 
OR (95% CI) Cancer case  
n (%) 
CHD control   
n (%) 
OR (95% CI) Cancer case  
n (%) 
CHD control   
n (%) 
OR (95% CI) 
Updated smoking status 
Al l  cancers 
Lung  
Bladder 
Upper aerodigestive tract 
 
 
4541 (37)  
2873 (31)  
1172 (57)  
496 (50)  
 
 
9627 (78) 
7224 (77) 
1620 (79 
783 (79)  
 
0·18 (0·17-0·19) 
0·14 (0·13-0·15) 
0·38 (0·33-0·44) 
0·27 (0·22-0·33)  
 
3962 (37) 
2454 (31) 
1055 (57) 
453 (50) 
 
8437 (78) 
6253 (78) 
1466 (79) 
718 (79) 
 
0.18 (0.17-0.19) 
0.13 (0.12-0.14) 
0.38 (0.33-0.44) 
0.27 (0.22-0.33) 
 
2605 (62) 
1404 (60) 
851 (65) 
350 (61)  
 
 
3611 (86) 
1982 (84) 
1138 (87) 
502 (87)  
 
0·26 (0·23-0·29) 
0·25 (0·22-0·29) 
0·28 (0·22-0·34) 
0·23 (0·17-0·30)  
Advice to quit 
Al l  cancers 
Lung  
Bladder 
Upper aerodigestive tract 
 
2794 (23)  
1672 (18)  
809 (39)  
313 (31) 
 
5601 (45) 
4196 (45)  
925 (45)  
480 (48) 
 
0·38 (0·36-0·40) 
0·28 (0·26-0·30) 
0·87 (0·76-0·99) 
0·50 (0·41-0·60) 
 
2636 (24) 
1564 (19) 
774 (42) 
298 (33) 
 
5245 (48) 
3907 (49) 
880 (48) 
458 (50) 
 
0.36 (0.34-0.38) 
0.26 (0.24-0.28)  
0.86 (0.75-0.98) 
0.50 (0.41-0.60) 
 
1630 (39) 
810 (34)  
594 (46)  
226 (39) 
 
2156 (51) 
1182 (50) 
669 (51) 
305 (53) 
 
0·60 (0·55-0·66) 
0·49 (0·43-0·56) 
0·84 (0·70-0·99) 
0·58 (0·46-0·74) 
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Prescriptions 
Al l  cancers 
Lung  
Bladder 
Upper aerodigestive tract 
 
 
1504 (12)   
989 (11)  
291 (14)  
224 (22) 
 
2560 (21) 
1950 (21)  
386 (19)  
224 (22) 
 
0·67 (0·63-0·73) 
0·58 (0·53-0·63) 
0·96 (0·81-1·16) 
1·00 (0·80-1·24) 
 
1439 (13) 
940 (12)  
279 (15) 
220 (24) 
 
2426 (22) 
1835 (23) 
373 (20) 
218 (24) 
 
0.67 (0.62-0.72) 
0.57 (0.52-0.63) 
0.97 (0.81-1.16) 
1 .03 (0.83-1.29) 
 
882 (21)  
498 (21)  
226 (17)  
158 (27) 
 
967 (23) 
547 (23) 
280 (22) 
140 (24) 
 
1·05 (0·94-1·17) 
1·06 (0·91-1·23) 
1·02 (0·83-1·25) 
1·18 (0·89-1·55) 
*Number for cancer subgroups and 1:1 matched CHD controls - lung n= 9347, bladder n= 2050, UAT n= 996 
**Number for cancer subgroups and 1:1 matched CHD controls - lung n=8037, bladder n= 1848, UAT n= 909 
**Number for cancer subgroups and 1:1 matched CHD controls - lung n=2350, bladder n=1302, UAT n=576 
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Table 3: Number (%) cancer and CHD patients diagnosed between 1999 and 2013 quitting within the first year after diagnosis, and 
odds ratio (OR) for quitting in cancer patients relative to matched CHD patients  
 Patients with at least 1 update of smoking 
status 
 
(all cancer n= 3706, CHD control n=3706) 
Patients with at least 1 update of smoking status 
and 1 year+ survivors only  
(all cancer n=2253, CHD control n=2253) 
 Cancer case  
n (%) 
CHD control  
n (%) 
OR (95% CI) Cancer case  
n (%) 
CHD control  
n (%) 
OR (95% CI) 
Quitting 
All cancers  
Lung cancer 
Bladder cancer 
Upper aerodigestive 
tract cancer 
 
1359 (36·7)  
885 (37·8)  
289 (30·6)  
185 (43·8) 
 
1645 (44·4)   
1019 (43·6)  
445 (47·1)  
181 (42·9) 
 
0·76 (0·69-0·84) 
0·85 (0·75-0·97) 
0·48 (0·39-0·59) 
1·03 (0·78-1·35) 
 
863 (38·3)   
487 (41·3)  
232 (30·7)  
144 (45·0) 
 
1004 (44·6)  
510 (43·3)  
351 (46·5)  
143 (44·7) 
 
0·82 (0·72-0·93) 
1·04 (0·87-1·25) 
0·50 (0·40-0·63) 
1·00 (0·73-1·38) 
*Number for cancer subgroups and matched CHD controls, lung n= 2340, bladder n= 944, UAT n= 422  
**Number for cancer subgroups and matched CHD controls, lung n= 1178, bladder n= 755, UAT n=320 
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Figure 1: Percentage of patients with smoking status updated, advice to quit, prescription of 
smoking cessation medications and quitting within the first year after diagnosis pre and post 
QOF (all cancer patients and matched CHD patients) between 1999 and 2013 
a. Smoking status (preQOF/postQOF OR 2·71 (95% CI 2·44-2·99), p interaction = 
0·86) 
b. Advice to quit (preQOF/postQOF OR 3·04 (95%CI 2·73-3·38), p interaction = 0·02) 
c. Prescriptions (preQOF/postQOF OR 1·79 (95%CI 1·56-2·05), p interaction = 0·89) 
 
